Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome

Beata Holkovaa Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;b Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USAView further author information

Danielle Shafera Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;b Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USAView further author information

Victor Yazbecka Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;b Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USAView further author information

Sandeep Davec Department of Medicine, Duke University, Durham, NC, USAView further author information

Prithviraj Bosea Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;b Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA

https://orcid.org/0000-0002-4343-5712 View further author information

Mary Beth Tombesa Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USAView further author information

Ellen Shradera Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USAView further author information

Wen Wana Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;d Department of Statistics, Virginia Commonwealth University, Richmond, VA, USAView further author information

Dipankar Bandyopadhyaya Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;d Department of Statistics, Virginia Commonwealth University, Richmond, VA, USAView further author information

Caryn Weira Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USAView further author information

Elizabeth B. Collinsa Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USAView further author information

Amanda Garnetta Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USAView further author information

Maciej Kmieciaka Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USAView further author information

John D. Robertsa Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;b Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USAView further author information

Guillermo Garcia-Maneroe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information

Steven Granta Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;b Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA;f Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA;g Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA;h The Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USACorrespondence[email protected]
View further author information

show all

Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome

Supplemental Material

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date